39 results on '"Willerslev-Olsen, Andreas"'
Search Results
2. Endolysin Inhibits Skin Colonization by Patient-Derived Staphylococcus Aureus and Malignant T-Cell Activation in Cutaneous T-Cell Lymphoma
- Author
-
Pallesen, Emil M.H., Gluud, Maria, Vadivel, Chella Krishna, Buus, Terkild B., de Rooij, Bob, Zeng, Ziao, Ahmad, Sana, Willerslev-Olsen, Andreas, Röhrig, Christian, Kamstrup, Maria R., Bay, Lene, Lindahl, Lise, Krejsgaard, Thorbjørn, Geisler, Carsten, Bonefeld, Charlotte M., Iversen, Lars, Woetmann, Anders, Koralov, Sergei B., Bjarnsholt, Thomas, Frieling, Johan, Schmelcher, Mathias, and Ødum, Niels
- Published
- 2023
- Full Text
- View/download PDF
3. Malignant T cells induce skin barrier defects through cytokine-mediated JAK/STAT signaling in cutaneous T-cell lymphoma
- Author
-
Gluud, Maria, Pallesen, Emil M. H., Buus, Terkild B., Gjerdrum, Lise Mette Rahbek, Lindahl, Lise M., Kamstrup, Maria R., Bzorek, Michael, Danielsen, Maria, Bech, Rikke, Monteiro, Madalena N., Blümel, Edda, Willerslev-Olsen, Andreas, Lykkebo-Valløe, Anders, Vadivel, Chella Krishna, Krejsgaard, Thorbjørn, Bonefeld, Charlotte Menne, Geisler, Carsten, Becker, Jürgen C., Koralov, Sergei B., Iversen, Lars, Litman, Thomas, Woetmann, Anders, and Ødum, Niels
- Published
- 2023
- Full Text
- View/download PDF
4. Staphylococcus aureus Induces Signal Transducer and Activator of Transcription 5‒Dependent miR-155 Expression in Cutaneous T-Cell Lymphoma
- Author
-
Willerslev-Olsen, Andreas, Gjerdrum, Lise Mette Rahbek, Lindahl, Lise M., Buus, Terkild B., Pallesen, Emil M.H., Gluud, Maria, Bzorek, Michael, Nielsen, Boye S., Kamstrup, Maria R., Rittig, Anne Hald, Bonefeld, Charlotte M., Krejsgaard, Thorbjørn, Geisler, Carsten, Koralov, Sergei B., Litman, Thomas, Becker, Jurgen C., Woetmann, Anders, Iversen, Lars, and Odum, Niels
- Published
- 2021
- Full Text
- View/download PDF
5. Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma
- Author
-
Lindahl, Lise M., Willerslev-Olsen, Andreas, Gjerdrum, Lise M.R., Nielsen, Pia R., Blümel, Edda, Rittig, Anne H., Celis, Pamela, Herpers, Bjorn, Becker, Jürgen C., Stausbøl-Grøn, Birgitte, Wasik, Mariusz A., Gluud, Maria, Fredholm, Simon, Buus, Terkild B., Johansen, Claus, Nastasi, Claudia, Peiffer, Lukas, Kubat, Linda, Bzorek, Michael, Eriksen, Jens O., Krejsgaard, Thorbjørn, Bonefeld, Charlotte M., Geisler, Carsten, Mustelin, Tomas, Langhoff, Erik, Givskov, Michael, Woetmann, Anders, Kilian, Mogens, Litman, Thomas, Iversen, Lars, and Odum, Niels
- Published
- 2019
- Full Text
- View/download PDF
6. SATB1 in Malignant T Cells
- Author
-
Fredholm, Simon, Willerslev-Olsen, Andreas, Met, Özcan, Kubat, Linda, Gluud, Maria, Mathiasen, Sarah L., Friese, Christina, Blümel, Edda, Petersen, David L., Hu, Tengpeng, Nastasi, Claudia, Lindahl, Lise M., Buus, Terkild B., Krejsgaard, Thorbjørn, Wasik, Mariusz A., Kopp, Katharina L., Koralov, Sergei B., Persson, Jenny L., Bonefeld, Charlotte M., Geisler, Carsten, Woetmann, Anders, Iversen, Lars, Becker, Jürgen C., and Ødum, Niels
- Published
- 2018
- Full Text
- View/download PDF
7. Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study
- Author
-
Lindahl, Lise M., Besenbacher, Søren, Rittig, Anne H., Celis, Pamela, Willerslev-Olsen, Andreas, Gjerdrum, Lise M.R., Krejsgaard, Thorbjørn, Johansen, Claus, Litman, Thomas, Woetmann, Anders, Odum, Niels, and Iversen, Lars
- Published
- 2018
- Full Text
- View/download PDF
8. Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in Sézary syndrome
- Author
-
Willerslev-Olsen, Andreas, Buus, Terkild B., Nastasi, Claudia, Blümel, Edda, Gluud, Maria, Bonefeld, Charlotte M., Geisler, Carsten, Lindahl, Lise M., Vermeer, Maarten, Wasik, Mariusz A., Iversen, Lars, Becker, Jürgen C., Andersen, Mads Hald, Gjerdrum, Lise M. R., Litvinov, Ivan V., Litman, Thomas, Krejsgaard, Thorbjørn, Woetmann, Anders, and Ødum, Niels
- Published
- 2020
- Full Text
- View/download PDF
9. Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma
- Author
-
Willerslev-Olsen, Andreas, Krejsgaard, Thorbjørn, Lindahl, Lise M., Litvinov, Ivan V., Fredholm, Simon, Petersen, David L., Nastasi, Claudia, Gniadecki, Robert, Mongan, Nigel P., Sasseville, Denis, Wasik, Mariusz A., Bonefeld, Charlotte M., Geisler, Carsten, Woetmann, Anders, Iversen, Lars, Kilian, Mogens, Koralov, Sergei B., and Odum, Niels
- Published
- 2016
- Full Text
- View/download PDF
10. Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma
- Author
-
Krejsgaard, Thorbjørn, Litvinov, Ivan V., Wang, Yang, Xia, Lixin, Willerslev-Olsen, Andreas, Koralov, Sergei B., Kopp, Katharina L., Bonefeld, Charlotte M., Wasik, Mariusz A., Geisler, Carsten, Woetmann, Anders, Zhou, Youwen, Sasseville, Denis, and Odum, Niels
- Published
- 2013
- Full Text
- View/download PDF
11. miRNA Signature in Early-stage Mycosis Fungoides.
- Author
-
SØRENSEN, Sissel T., LITMAN, Thomas, GLUUD, Maria, CELIS, Pamela, TORRES-RUSILLO, Sara, WILLERSLEV-OLSEN, Andreas, ØDUM, Niels, IVERSEN, Lars, and LINDAHL, Lise M.
- Subjects
MYCOSIS fungoides ,GENE expression ,MICRORNA ,CUTANEOUS T-cell lymphoma - Abstract
Altered miRNA expressions are assigned pathogenic properties in several cancers including mycosis fungoides and could play a role in the early onset of the disease. The aim of this study was to examine disease-specific miRNA expression in early-stage mycosis fungoides patch and plaque lesions. A quantitative real-time PCR platform of 384 human miRNAs was used to study miRNA expression in 154 diagnostic mycosis fungoides biopsies. A total of 110 miRNAs were significantly differentially expressed (>2-fold, p < 0.05) between plaque lesions and healthy controls, and 90 miRNAs (>2-fold, p < 0.05) differed between patch lesions and healthy controls. Moreover, 13 miRNAs differed in expression between patch and plaque lesions. Early-stage mycosis fungoides exhibited miRNA features that overlapped with those of psoriasis. However, 39 miRNAs, including miR-142-3p, miR-150 and miR-146b, were specific to mycosis fungoides. In conclusion, early-stage mycosis fungoides expresses a distinct miRNA profile, indicating that miRNAs could play a role in the early development of mycosis fungoides. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. The Thioredoxin-Interacting Protein TXNIP Is a Putative Tumour Suppressor in Cutaneous T-Cell Lymphoma.
- Author
-
Stolearenco, Veronica, Levring, Trine B., Nielsen, Helene Myrtue, Lindahl, Lise, Fredholm, Simon, Kongsbak-Wismann, Martin, Willerslev-Olsen, Andreas, Buus, Terkild B., Nastasi, Claudia, Hu, Tengpeng, Gluud, Maria, Côme, Christophe R.M., Krejsgaard, Thorbjørn, Iversen, Lars, Bonefeld, Charlotte Menné, Grønbæk, Kirsten, Met, Özcan, Woetmann, Anders, Ødum, Niels, and Geisler, Carsten
- Subjects
CUTANEOUS T-cell lymphoma ,THIOREDOXIN-interacting protein ,CANCER cells ,T cells ,CELL lines ,O6-Methylguanine-DNA Methyltransferase ,ANAPLASTIC lymphoma kinase - Abstract
Background: The thioredoxin-interacting protein (TXNIP) is involved in cellular metabolism and cell proliferation, and recently, deficient expression of TXNIP has been associated with progression and poor outcome for cancer patients. Objectives: To assess TXNIP expression and function in malignant T cells from cutaneous T-cell lymphoma (CTCL). Methods: CTCL-derived malignant (MyLa2059, PB2B) and non-malignant (MyLa1850) cell lines were analysed by Western blotting and qPCR for TXNIP expression. Subsequently, the malignant CTCL cell lines were treated with GSK126 – an inhibitor of enhancer of zeste homolog 2 (EZH2) methyltransferase activity or assessed by bisulphite sequencing for TXNIP promoter methylation. Methylation was also assessed with the demethylating agent 5-azacytidine (5AZA). Finally, TXNIP was overexpressed in the malignant PB2B cell line via plasmid transduction, and the effect of TXNIP was further analysed by flow cytometry. Results: We report on low expression of TXNIP protein in all cell lines representing different subtypes and stages of CTCL when compared to non-malignant T cells. Epigenetic silencing and other mechanisms were involved in the repression of TXNIP whereas forced expression of TXNIP strongly inhibited proliferation of malignant T cells. Conclusions: Epigenetic silencing and other as yet unknown mechanisms repress TXNIP expression in malignant T cells. As forced expression of TXNIP inhibits malignant proliferation, we propose that TXNIP is a putative tumour suppressor in CTCL. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. MicroRNA-93 Targets p21 and Promotes Proliferation in Mycosis Fungoides T Cells.
- Author
-
Gluud, Maria, Fredholm, Simon, Blümel, Edda, Willerslev-Olsen, Andreas, Buus, Terkild Brink, Nastasi, Claudia, Krejsgaard, Thorbjørn, Bonefeld, Charlotte Menné, Woetmann, Anders, Iversen, Lars, Litman, Thomas, Geisler, Carsten, Ødum, Niels, and Lindahl, Lise M.
- Subjects
MYCOSIS fungoides ,T cells ,CYCLIN-dependent kinases ,CANCER cells ,CUTANEOUS T-cell lymphoma ,CYCLIN-dependent kinase inhibitors ,CELL cycle - Abstract
Background: Mycosis fungoides (MF), the most common form of cutaneous T-cell lymphoma (CTCL), is a lymphoproliferative disorder characterized by proliferation of malignant T cells in a chronic inflammatory environment in the skin. The nature of MF is still not fully understood, but aberrant microRNA (miR) expression and function seem to play an important role in the pathogenesis and disease progression and have been proposed as a putative disease marker. Recent studies have reported aberrant expression of miR-93 in situin MF lesions and linked dysregulated miR-93 expression to advanced stages of MF. However, the pathophysiological role of miR-93 in MF is unknown. Objective: Here, we provide the first evidence that miR-93 targets the cell cycle regulator cyclin-dependent kinase inhibitor p21 and promotes growth of malignant T cells in MF. Methods/Results: Thus, inhibition of miR-93 in MF patient-derived malignant T-cell lines increases expression of p21 and inhibition of malignant proliferation. Notably, treatment with the histone deacetylase inhibitor Vorinostat (SAHA) reduces miR-93 expression and enhances p21 expression in the malignant T cells. Importantly, transfection with an miR-93 mimic partly blocks SAHA-induced p21 expression. Conclusions: we provide evidence that enhanced expression of the putative oncogenic miR, miR-93, represses the cell cycle inhibitor p21 and promotes proliferation of malignant T cells. Moreover, we demonstrate that SAHA triggers p21 expression – at least partly – through an inhibition of miR-93. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Expression of the Voltage-Gated Potassium Channel Kv1.3 in Lesional Skin from Patients with Cutaneous T-Cell Lymphoma and Benign Dermatitis.
- Author
-
Hu, Tengpeng, Krejsgaard, Thorbjørn, Nastasi, Claudia, Buus, Terkild Brink, Nansen, Anneline, Hald, Andreas, Spee, Pieter, Nielsen, Pia Rude, Blümel, Edda, Gluud, Maria, Willerslev-Olsen, Andreas, Woetmann, Anders, Bzorek, Michael, Eriksen, Jens O., Ødum, Niels, Rahbek Gjerdrum, Lise Mette, Buus, Terkild Brink, Nielsen, Pia Rude, Eriksen, Jens O, and Rahbek Gjerdrum, Lise Mette
- Subjects
CUTANEOUS T-cell lymphoma ,POTASSIUM channels ,MYCOSIS fungoides ,SKIN inflammation ,SEZARY syndrome ,T cells ,BIOPSY ,SKIN ,IMMUNOHISTOCHEMISTRY ,ARTHRITIS Impact Measurement Scales ,SKIN tumors ,MEMBRANE proteins ,CELL lines ,CHEMICAL inhibitors - Abstract
Background: The voltage-gated potassium channel Kv1.3 (KCNA3) is expressed by effector memory T cells (TEM) and plays an important role in their activation and proliferation. Mycosis fungoides (MF), the most common subtype of cutaneous T-cell lymphoma (CTCL), was recently proposed to be a malignancy of skin-resident TEM. However, the expression of Kv1.3 in CTCL has not been investigated.Objectives: This study aims to examine the expression of Kv1.3 in situ and in vitro in CTCL.Methods: The expression of Kv1.3 was examined by immunohistochemistry in skin lesions from 38 patients with MF, 4 patients with Sézary syndrome (SS), and 27 patients with benign dermatosis. In 4 malignant T-cell lines of CTCL (Myla2059, PB2B, SeAx, and Mac2a) and a non-malignant T-cell line (MyLa1850), the expression of Kv1.3 was determined by flow cytometry. The proliferation of those cell lines treated with various concentrations of Kv1.3 inhibitor ShK was measured by 3H-thymdine incorporation.Results: Half of the MF patients (19/38) displayed partial Kv1.3 expression including 1 patient with moderate Kv1.3 positivity, while the other half (19/38) exhibited Kv1.3 negativity. An almost identical distribution was observed in patients with benign conditions, that is, 44.4% (12/27) were partially positive for Kv1.3 including 1 patient with moderate Kv1.3 positivity, while 55.6% (15/27) were Kv1.3 negative. In contrast, 3 in 4 SS patients displayed partial Kv1.3 positivity including 2 patients with weak staining and 1 with moderate staining, while 1 in 4 SS patients was Kv1.3 negative. In addition, all malignant T-cell lines, and a non-malignant T-cell line, displayed low Kv1.3 surface expression with a similar pattern. Whereas 2 cell lines (PB2B and Mac2a) were sensitive to Kv1.3 blockade, the other 2 (Myla2059 and SeAx) were completely resistant.Conclusions: We provide the first evidence of a heterogeneous Kv1.3 expression in situ in CTCL lesions. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
15. Staphylococcus aureus alpha-toxin inhibits CD8+ T cell-mediated killing of cancer cells in cutaneous T-cell lymphoma.
- Author
-
Blümel, Edda, Munir Ahmad, Shamaila, Nastasi, Claudia, Willerslev-Olsen, Andreas, Gluud, Maria, Fredholm, Simon, Hu, Tengpeng, Surewaard, Bas G. J., Lindahl, Lise M., Fogh, Hanne, Koralov, Sergei B., Rahbek Gjerdrum, Lise Mette, Clark, Rachael A., Iversen, Lars, Krejsgaard, Thorbjørn, Bonefeld, Charlotte Menné, Geisler, Carsten, Becker, Jürgen C., Woetmann, Anders, and Andersen, Mads Hald
- Subjects
CUTANEOUS T-cell lymphoma ,CANCER cells ,STAPHYLOCOCCUS aureus ,T cells ,CELL death ,SEZARY syndrome ,CYANOBACTERIAL toxins - Abstract
and its toxins have been linked to disease progression and mortality in advanced stages of cutaneous T-cell lymphoma (CTCL). CD8
+ T cells play a crucial role in anti-cancer responses and high CD8+ T cell numbers in tumor lesions are associated with a favorable prognosis in CTCL. Here, we show that CD8+ T cells from both healthy donors and Sézary syndrome patients are highly susceptible to cell death induced by Staphylococcal alpha-toxin, whereas malignant T cells are not. Importantly, alpha-toxin almost completely blocks cytotoxic killing of CTCL tumor cells by peptide-specific CD8+ T cells, leading to their escape from induced cell death and continued proliferation. These findings suggest that alpha-toxin may favor the persistence of malignant CTCL cells in vivo by inhibiting CD8+ T cell cytotoxicity. Thus, we propose a novel mechanism by which colonization with Staphylococcus aureus may contribute to cancer immune evasion and disease progression in CTCL. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
16. Staphylococcal alpha-toxin tilts the balance between malignant and non-malignant CD4+ T cells in cutaneous T-cell lymphoma.
- Author
-
Blümel, Edda, Willerslev-Olsen, Andreas, Gluud, Maria, Lindahl, Lise M., Fredholm, Simon, Nastasi, Claudia, Krejsgaard, Thorbjørn, Surewaard, Bas G. J., Koralov, Sergei B., Hu, Tengpeng, Persson, Jenny L., Bonefeld, Charlotte Menné, Geisler, Carsten, Iversen, Lars, Becker, Jürgen C., Andersen, Mads Hald, Woetmann, Anders, Buus, Terkild Brink, and Ødum, Niels
- Subjects
- *
T cells , *CUTANEOUS T-cell lymphoma , *SEZARY syndrome , *CELL death , *STAPHYLOCOCCUS aureus - Abstract
Staphylococcus aureus is implicated in disease progression in cutaneous T-cell lymphoma (CTCL). Here, we demonstrate that malignant T cell lines derived from CTCL patients as well as primary malignant CD4+ T cells from Sézary syndrome patients are considerably more resistant to alpha-toxin-induced cell death than their non-malignant counterparts. Thus, in a subset of Sézary syndrome patients the ratio between malignant and non-malignant CD4+ T cells increases significantly following exposure to alpha-toxin. Whereas toxin-induced cell death is ADAM10 dependent in healthy CD4+ T cells, resistance to alpha-toxin in malignant T cells involves both downregulation of ADAM10 as well as other resistance mechanisms. In conclusion, we provide first evidence that Staphylococcus aureus derived alpha-toxin can tilt the balance between malignant and non-malignant CD4+ T cells in CTCL patients. Consequently, alpha-toxin may promote disease progression through positive selection of malignant CD4+ T cells, identifying alpha-toxin as a putative drug target in CTCL. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. STAT5 induces miR-21 expression in cutaneous T cell lymphoma
- Author
-
Lindahl, Lise M., Fredholm, Simon, Joseph, Claudine, Nielsen, Boye Schnack, Willerslev-Olsen, Andreas, Gluud, Maria, Petersen, David L., Sibbesen, Nina, Hu, Tengpeng, Nastasi, Claudia, Persson, Jenny L., Mongan, Nigel P., Wasik, Mariusz A., Litvinov, Ivan V., Sasseville, Denis, Koralov, Sergei B., Bonefeld, Charlotte M., Geisler, Carsten, Woetmann, Anders, Ralfkiaer, Elisabeth, Iversen, Lars, and Odum, Niels
- Subjects
MiR-21, in situ, STAT5, IL-2, Cutaneous T-cell lymphoma (CTCL) - Abstract
In cutaneous T cell lymphomas (CTCL), miR-21 is aberrantly expressed in skin and peripheral blood and displays anti-apoptotic properties in malignant T cells. It is, however, unclear exactly which cells express miR-21 and what mechanisms regulate miR-21. Here, we demonstrate miR-21 expression in situ in both malignant and reactive lymphocytes as well as stromal cells. qRT-PCR analysis of 47 patients with mycosis fungoides (MF) and Sezary Syndrome (SS) confirmed an increased miR-21 expression that correlated with progressive disease. In cultured malignant T cells miR-21 expression was inhibited by Tofacitinib (CP-690550), a clinical-grade JAK3 inhibitor. Chromatin immunoprecipitation (ChIP) analysis showed direct binding of STAT5 to the miR-21 promoter. Cytokine starvation ex vivo triggered a decrease in miR-21 expression, whereas IL-2 induced an increased miR-21 expression in primary SS T cells and cultured cytokine-dependent SS cells (SeAx). siRNA-mediated depletion of STAT5 inhibited constitutive- and IL-2-induced miR-21 expression in cytokine-independent and dependent T cell lines, respectively. IL-15 and IL-2 were more potent than IL-21 in inducing miR-21 expression in the cytokine-dependent T cells. In conclusion, we provide first evidence that miR-21 is expressed in situ in CTCL skin lesions, induced by IL-2 and IL-15 cytokines, and is regulated by STAT5 in malignant T cells. Thus, our data provide novel evidence for a pathological role of IL-2Rg cytokines in promoting expression of the oncogenic miR-21 in CTCL.
- Published
- 2016
18. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma
- Author
-
Sibbesen, Nina A., Kopp, Katharina L., Litvinov, Ivan V., Willerslev-Olsen, Andreas, Fredholm, Simon, Petersen, David L., Nastasi, Claudia, Lindahl, Lise M., Gniadecki, Robert, Mongan, Nigel P., Sasseville, Denis, Wasik, Mariusz A., Iversen, Lars, Bonefeld, Charlotte M., Geisler, Carsten, Woetmann, Anders, and Odum, Niels
- Subjects
hemic and lymphatic diseases - Abstract
Aberrant activation of Janus kinase-3 (Jak3) and its key down-stream effectors, Signal Transducer and Activator of Transcription-3 (STAT3) and STAT5, is a key feature of malignant transformation in cutaneous T-cell lymphoma (CTCL). However, it remains only partially understood how Jak3/STAT activation promotes lymphomagenesis. Recently, non-coding microRNAs (miRNAs) have been implicated in the pathogenesis of this malignancy. Here, we show that (i) malignant T cells display a decreased expression of a tumor suppressor miRNA, miR-22, when compared to non-malignant T cells, (ii) STAT5 binds the promoter of the miR-22 host gene, and (iii) inhibition of Jak3, STAT3, and STAT5 triggers increased expression of pri-miR-22 and miR-22. Curcumin, a nutrient with anti-Jak3 activity and histone deacetylase inhibitors (HDACi) also trigger increased expression of pri-miR-22 and miR-22. Transfection of malignant T cells with recombinant miR-22 inhibits the expression of validated miR-22 targets including NCoA1, a transcriptional co-activator in others cancers, as well as HDAC6, MAX, MYCBP, PTEN, and CDK2, which have all been implicated in CTCL pathogenesis. In conclusion, we provide the first evidence that de-regulated Jak3/STAT3/STAT5 signalling in CTCL cells represses the expression of the gene encoding miR-22, a novel tumor suppressor miRNA.
- Published
- 2015
19. A novel BLK-induced tumor model.
- Author
-
Petersen, David Leander, Berthelsen, Jens, Willerslev-Olsen, Andreas, Fredholm, Simon, Dabelsteen, Sally, Bonefeld, Charlotte Menné, Geisler, Carsten, and Woetmann, Anders
- Subjects
PROTEIN-tyrosine kinases ,PROTEIN kinases ,B cell receptors ,CELL receptors ,ONCOGENES - Abstract
B-lymphoid tyrosine kinase (BLK) is a non-receptor tyrosine kinase belonging to the SRC family kinases. BLK is known to be functionally involved in B-cell receptor signaling and B-cell development. New evidence suggests that B-lymphoid tyrosine kinase is ectopically expressed and is a putative oncogene in cutaneous T-cell lymphoma and other T-cell malignancies. However, little is known about the role of BLK in lymphomagenesis, and the oncogenic function seems to depend on the cellular context. Importantly, BLK is also ectopically expressed in other hematological and multiple non-hematological malignancies including breast, kidney, and lung cancers, suggesting that BLK could be a new potential target for therapy. Here, we studied the oncogenic potential of human BLK. We found that engrafted Ba/F3 cells stably expressing constitutive active human BLK formed tumors in mice, whereas neither Ba/F3 cells expressing wild type BLK nor non-transfected Ba/F3 cells did. Inhibition of BLK with the clinical grade and broadly reacting SRC family kinase inhibitor dasatinib inhibited growth of BLK--induced tumors. In conclusion, our study provides evidence that human BLK is a true proto-oncogene capable of inducing tumors, and we demonstrate a novel BLK activity-dependent tumor model suitable for studies of BLK--driven lymphomagenesis and screening of novel BLK inhibitors in vivo. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
20. Epigenetic Silencing of Mir-203 Contributes to IL2Rb Overexpression and Malignant Transformation in Cutaneous T-Cell Lymphoma
- Author
-
Ralfkiaer, Ulrik, Jansson, Martin, Kopp, Katharina, Willerslev-Olsen, Andreas, Asmar, Fazila, Krejsgaard, Thorbjorn, Brown, Peter de Nully, Gniadecki, Robert, Woetman, Anders, Lund, Anders, Odum, Niels, and Groenbaek, Kirsten
- Published
- 2014
- Full Text
- View/download PDF
21. Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation.
- Author
-
Krejsgaard, Thorbjørn, Willerslev-Olsen, Andreas, Lindahl, Lise M., Bonefeld, Charlotte M., Koralov, Sergei B., Geisler, Carsten, Wasik, Mariusz A., Gniadecki, Robert, Kilian, Mogens, Iversen, Lars, Woetmann, Anders, and Odum, Niels
- Subjects
- *
STAPHYLOCOCCAL diseases , *ENTEROTOXINS , *LYMPHOMAS , *IMMUNODEFICIENCY , *ANTIBIOTICS - Abstract
Patients with cutaneous T-cell lymphoma (CTCL) are frequently colonized with Staphylococcus aureus (SA). Eradication of SA is, importantly, associated with significant clinical improvement, suggesting that SA promotes the disease activity, but the underlying mechanisms remain poorly characterized. Here, we show that SA isolates from involved skin express staphylococcal enterotoxins (SEs) that induce crosstalk between malignant and benign T cells leading to Stat3-mediated interleukin-10 (IL-10) production by the malignant T cells. The SEs did not stimulate the malignant T cells directly. Instead, SEs triggered a cascade of events involving cell-cell and asymmetric cytokine interactions between malignant and benign T cells, which stimulated the malignant T cells to express high levels of IL-10. Much evidence supports that malignant activation of the Stat3/IL-10 axis plays a key role in driving the immune dysregulation and severe immunodeficiency that characteristically develops in CTCL patients. The present findings thereby establish a novel link between SEs and immune dysregulation in CTCL, strengthening the rationale for antibiotic treatment of colonized patients with severe or progressive disease. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
22. IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF).
- Author
-
Willerslev-Olsen, Andreas, Litvinov, Ivan V., Fredholm, Simon M., Petersen, David L., Sibbesen, Nina A., Gniadecki, Robert, Qian Zhang, Bonefeld, Charlotte M., Wasik, Mariusz A., Geisler, Carsten, Zhou, Youwen, Woetmann, Anders, Sasseville, Denis, Krejsgaard, Thorbjørn, and Ødum, Niels
- Published
- 2014
- Full Text
- View/download PDF
23. Bacterial Toxins Fuel Disease Progression in Cutaneous T-Cell Lymphoma.
- Author
-
Willerslev-Olsen, Andreas, Krejsgaard, Thorbjørn, Lindahl, Lise M., Bonefeld, Charlotte Menne, Wasik, Mariusz A., Koralov, Sergei B., Geisler, Carsten, Kilian, Mogens, Iversen, Lars, Woetmann, Anders, and Odum, Niels
- Subjects
- *
T-cell lymphoma , *BACTERIAL diseases , *STAPHYLOCOCCUS aureus , *ENTEROTOXINS , *SUPERANTIGENS , *IMMUNODEFICIENCY - Abstract
In patients with cutaneous T-cell lymphoma (CTCL) bacterial infections constitute a major clinical problem caused by compromised skin barrier and a progressive immunodeficiency. Indeed, the majority of patients with advanced disease die from infections with bacteria, e.g., Staphylococcus aureus. Bacterial toxins such as staphylococcal enterotoxins (SE) have long been suspected to be involved in the pathogenesis in CTCL. Here, we review links between bacterial infections and CTCL with focus on earlier studies addressing a direct role of SE on malignant T cells and recent data indicating novel indirect mechanisms involving SE- and cytokine-driven cross-talk between malignant- and non-malignant T cells. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
24. Vascular endothelial growth factor receptor-3 expression in mycosis fungoides.
- Author
-
Pedersen, Ida Holst, Willerslev-Olsen, Andreas, Vetter-Kauczok, Claudia, Krejsgaard, Thorbjørn, Lauenborg, Britt, Kopp, Katharina Luise, Geisler, Carsten, Bonefeld, Charlotte M., Zhang, Qian, Wasik, Mariusz A., Dabelsteen, Sally, Woetmann, Anders, Becker, Jurgen C., and Odum, Niels
- Subjects
- *
VASCULAR endothelial growth factor receptors , *MYCOSIS fungoides , *LYMPHOMAS , *TUMORS , *STROMAL cells , *T cells - Abstract
Here, we have studied vascular endothelial growth factor receptor-3 (VEGFR-3) expression in mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma (CTCL). Immunohistochemistry revealed that in two-thirds of 34 patients, VEGFR-3 was expressed in situ by both tumor and stromal cells irrespective of the disease stage. The natural VEGFR-3 ligand, VEGF-C, partially protected malignant T-cell lines from growth inhibition by the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA). Whereas the malignant T cells did not produce VEGF-C in vitro, its expression was induced during tumor formation in vivo in a xenograft mouse model of MF. In conclusion, malignant and stromal cells express high levels of VEGFR-3 in all stages of MF. Moreover, malignant T cells trigger enhanced VEGF-C expression in fibroblasts, suggesting that cross-talk between tumor and stromal cells plays a role in lymphangiogenesis and possibly disease progression. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
25. JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T Cell Lymphoma (CTCL).
- Author
-
Vadivel, Chella Krishna, Gluud, Maria, Torres-Rusillo, Sara, Boding, Lasse, Willerslev-Olsen, Andreas, Buus, Terkild B., Nielsen, Tea Kirkegaard, Persson, Jenny L., Bonefeld, Charlotte M., Geisler, Carsten, Krejsgaard, Thorbjorn, Fuglsang, Anja T., Odum, Niels, and Woetmann, Anders
- Subjects
CELL nuclei ,GENE expression ,PHOSPHORYLATION ,SKIN diseases ,T cells ,TRANSFERASES ,NUCLEAR proteins ,SEZARY syndrome ,T-cell lymphoma ,SIGNAL peptides ,IN vitro studies ,JANUS kinases - Abstract
Simple Summary: JAK3 plays an important role in the pathogenesis of cutaneous T cell lymphoma. JAK3 belongs to the Janus kinase family of receptor-associated tyrosine kinases located in cytoplasm adjacent to the plasma membrane. In this study, we show that JAK3 can also be ectopically expressed in the nucleus in CTCL cell lines and primary cells from CTCL patients. Importantly, JAK3 interacts with the nuclear protein RNA polymerase II and phosphorylates Histone H3. Thus, our data provide first evidence for nuclear expression of JAK3 and interactions with key nuclear proteins in malignant T cells suggesting a novel non-canonical role in CTCL. Perturbation in JAK-STAT signaling has been reported in the pathogenesis of cutaneous T cell lymphoma (CTCL). JAK3 is predominantly associated with the intra-cytoplasmic part of IL-2Rγc located in the plasma membrane of hematopoietic cells. Here we demonstrate that JAK3 is also ectopically expressed in the nucleus of malignant T cells. We detected nuclear JAK3 in various CTCL cell lines and primary malignant T cells from patients with Sézary syndrome, a leukemic variant of CTCL. Nuclear localization of JAK3 was independent of its kinase activity whereas STAT3 had a modest effect on nuclear JAK3 expression. Moreover, JAK3 nuclear localization was only weakly affected by blockage of nuclear export. An inhibitor of the nuclear export protein CRM1, Leptomycin B, induced an increased expression of SOCS3 in the nucleus, but only a weak increase in nuclear JAK3. Importantly, immunoprecipitation experiments indicated that JAK3 interacts with the nuclear protein POLR2A, the catalytic subunit of RNA Polymerase II. Kinase assays showed tyrosine phosphorylation of recombinant human Histone H3 by JAK3 in vitro—an effect which was blocked by the JAK inhibitor (Tofacitinib citrate). In conclusion, we provide the first evidence of nuclear localization of JAK3 in malignant T cells. Our findings suggest that JAK3 may have a cytokine-receptor independent function in the nucleus of malignant T cells, and thus a novel non-canonical role in CTCL. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
26. MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas.
- Author
-
Gluud, Maria, Willerslev-Olsen, Andreas, Gjerdrum, Lise Mette Rahbek, Lindahl, Lise M., Buus, Terkild B., Andersen, Mads Hald, Bonefeld, Charlotte Menne, Krejsgaard, Thorbjorn, Litvinov, Ivan V., Iversen, Lars, Becker, Jürgen C., Persson, Jenny L., Koralov, Sergei B., Litman, Thomas, Geisler, Carsten, Woetmann, Anders, and Odum, Niels
- Subjects
- *
SKIN disease diagnosis , *SKIN disease treatment , *MYCOSIS fungoides , *SKIN diseases , *T-cell lymphoma , *MICRORNA - Abstract
Cutaneous T-cell lymphoma (CTCL) represents a heterogeneous group of potentially devastating primary skin malignancies. Despite decades of intense research efforts, the pathogenesis is still not fully understood. In the early stages, both clinical and histopathological diagnosis is often difficult due to the ability of CTCL to masquerade as benign skin inflammatory dermatoses. Due to a lack of reliable biomarkers, it is also difficult to predict which patients will respond to therapy or progress towards severe recalcitrant disease. In this review, we discuss recent discoveries concerning dysregulated microRNA (miR) expression and putative pathological roles of oncogenic and tumor suppressive miRs in CTCL. We also focus on the interplay between miRs, histone deacetylase inhibitors, and oncogenic signaling pathways in malignant T cells as well as the impact of miRs in shaping the inflammatory tumor microenvironment. We highlight the potential use of miRs as diagnostic and prognostic markers, as well as their potential as therapeutic targets. Finally, we propose that the combined use of miR-modulating compounds with epigenetic drugs may provide a novel avenue for boosting the clinical efficacy of existing anti-cancer therapies in CTCL. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
27. Bio-O1-07 - miRNA signature in early-stage mycosis fungoides.
- Author
-
Sørensen, Sissel T, Litman, Thomas, Gluud, Maria, Celis, Pamela, Torres-Rusillo, Sara, Willerslev-Olsen, Andreas, Odum, Niels, Iversen, Lars, and Lindahl, Lise M
- Subjects
- *
MYCOSIS fungoides , *MICRORNA , *CONFERENCES & conventions - Abstract
Altered miRNA expressions are assigned pathogenic properties in several cancers including mycosis fungoides (MF) and could play a role in the early onset of the disease. To examine disease specific miRNA expression in early-stage MF patch and plaque lesions. We used a qRT-PCR platform of 384 human miRNAs to study the miRNA expression in 154 diagnostic MF biopsies. One-hundred-and-ten miRNAs were significantly differentially expressed (>2-fold, P<0.05) between plaque lesions and healthy controls, and 90 miRNAs (>2-fold, P<0.05) differed between patch lesions and healthy controls. Moreover, 13 miRNAs differed in expression between patch and plaque lesions. Early-stage MF exhibited miRNA features overlapping with psoriasis. However, 39 miRNAs, including miR-142-3p, miR-150 and miR-146b, were MF specific. Early-stage MF express a distinct miRNA profile indicating that miRNAs play a role in the early development of MF. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
28. MicroRNA-106b Regulates Expression of the Tumour Suppressors p21 and TXNIP and Promotes Tumour Cell Proliferation in Mycosis Fungoides.
- Author
-
Lindahl LM, Gluud M, Emmanuel T, Thomsen EA, Hu T, Rittig AH, Celis P, Stolearenco V, Krejsgaard T, Johansen C, Willerslev-Olsen A, Buus TB, Woetmann A, Aagaard L, Geisler C, Litman T, Mikkelsen JG, Odum N, and Iversen L
- Subjects
- Carrier Proteins, Cell Proliferation, Humans, Prognosis, MicroRNAs genetics, Mycosis Fungoides genetics, Skin Neoplasms genetics
- Abstract
A prognostic 3-miRNA classifier for early-stage mycosis fungoides has been developed recently, with miR-106b providing the strongest prognostic power. The aim of this study was to investigate the molecular function of miR-106b in mycosis fungoides disease progression. The cellular localization of miR-106b in mycosis fungoides skin biopsies was determined by in situ hybridization. The regulatory role of miR-106b was assessed by transient miR-106b inhibitor/mimic transfection of 2 mycosis fungoides derived cell lines, followed by quantitative real-time PCR (RT-qPCR), western blotting and a proliferation assay. MiR-106b was found to be expressed by dermal T-lymphocytes in mycosis fungoides skin lesions, and miR-106b expression increased with advancing mycosis fungoides stage. Transfection of miR-106b in 2 mycosis fungoides derived cell lines showed that miR-106b represses the tumour suppressors cyclin-dependent kinase inhibitor 1 (p21) and thioredoxin-interacting protein (TXNIP) and promotes mycosis fungoides tumour cell proliferation. In conclusion, these results substantiate that miR-106b has both a functional and prognostic role in progression of mycosis fungoides.
- Published
- 2020
- Full Text
- View/download PDF
29. Cellular Interactions and Inflammation in the Pathogenesis of Cutaneous T-Cell Lymphoma.
- Author
-
Stolearenco V, Namini MRJ, Hasselager SS, Gluud M, Buus TB, Willerslev-Olsen A, Ødum N, and Krejsgaard T
- Abstract
Cutaneous T-cell lymphoma (CTCL) comprises a group of lymphoproliferative diseases characterized by the accumulation of malignant T cells in chronically inflamed skin lesions. In early stages, the disease presents as skin patches or plaques covering a limited area of the skin and normally follows an indolent course. However, in a subset of patients the cutaneous lesions develop into tumors and the malignant T cells may spread to the lymphatic system, blood and internal organs with fatal consequences. Despite intensive research, the mechanisms driving disease progression remain incompletely understood. While most studies have focused on cancer cell-intrinsic oncogenesis, such as genetic and epigenetic events driving malignant transformation and disease progression, an increasing body of evidence shows that the interplay between malignant T cells and non-malignant cells plays a crucial role. Here, we outline some of the emerging mechanisms by which tumor, stromal and epidermal interactions may contribute to the progression of CTCL with particular emphasis on the crosstalk between fibroblasts, keratinocytes and malignant T cells., (Copyright © 2020 Stolearenco, Namini, Hasselager, Gluud, Buus, Willerslev-Olsen, Ødum and Krejsgaard.)
- Published
- 2020
- Full Text
- View/download PDF
30. Staphylococcus aureus alpha-toxin inhibits CD8 + T cell-mediated killing of cancer cells in cutaneous T-cell lymphoma.
- Author
-
Blümel E, Munir Ahmad S, Nastasi C, Willerslev-Olsen A, Gluud M, Fredholm S, Hu T, Surewaard BGJ, Lindahl LM, Fogh H, Koralov SB, Rahbek Gjerdrum LM, Clark RA, Iversen L, Krejsgaard T, Bonefeld CM, Geisler C, Becker JC, Woetmann A, Andersen MH, Buus TB, and Ødum N
- Subjects
- Humans, Leukocytes, Mononuclear, Staphylococcus aureus, Bacterial Toxins, CD8-Positive T-Lymphocytes drug effects, CD8-Positive T-Lymphocytes immunology, Hemolysin Proteins, Lymphoma, T-Cell, Cutaneous immunology, Skin Neoplasms immunology
- Abstract
Staphylococcus aureus and its toxins have been linked to disease progression and mortality in advanced stages of cutaneous T-cell lymphoma (CTCL). CD8
+ T cells play a crucial role in anti-cancer responses and high CD8+ T cell numbers in tumor lesions are associated with a favorable prognosis in CTCL. Here, we show that CD8+ T cells from both healthy donors and Sézary syndrome patients are highly susceptible to cell death induced by Staphylococcal alpha-toxin, whereas malignant T cells are not. Importantly, alpha-toxin almost completely blocks cytotoxic killing of CTCL tumor cells by peptide-specific CD8+ T cells, leading to their escape from induced cell death and continued proliferation. These findings suggest that alpha-toxin may favor the persistence of malignant CTCL cells in vivo by inhibiting CD8+ T cell cytotoxicity. Thus, we propose a novel mechanism by which colonization with Staphylococcus aureus may contribute to cancer immune evasion and disease progression in CTCL., (© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.)- Published
- 2020
- Full Text
- View/download PDF
31. Expression and function of Kv1.3 channel in malignant T cells in Sézary syndrome.
- Author
-
Hu T, Buus TB, Krejsgaard T, Nansen A, Lundholt BK, Spee P, Fredholm S, Petersen DL, Blümel E, Gluud M, Monteiro MN, Willerslev-Olsen A, Andersen MH, Straten PT, Met Ö, Stolearenco V, Fogh H, Gniadecki R, Nastasi C, Litman T, Woetmann A, Gjerdrum LMR, and Ødum N
- Abstract
The voltage-gated potassium channel Kv1.3 (KCNA3) is expressed by a subset of chronically activated memory T cells and plays an important role in their activation and proliferation. Here, we show that primary malignant T cells isolated from patients with Sézary syndrome (SS) express Kv1.3 and are sensitive to potent Kv1.3 inhibitors ShK and Vm24, but not sensitive to a less potent inhibitor [N17A/F32T]-AnTx. Kv1.3 blockade inhibits CD3/CD28-induced proliferation and IL-9 expression by SS cells in a concentration-dependent manner. In parallel, CD3/CD28-mediated CD25 induction is inhibited, whereas Kv1.3 blockade has no effect on apoptosis or cell death as judged by Annexin V and PI staining. In conclusion, we provide the first evidence that malignant T cells in SS express functional Kv1.3 channels and that Kv1.3 blockade inhibits activation-induced proliferation as well as cytokine and cytokine receptor expression in malignant T cells, suggesting that Kv1.3 is a potential target for therapy in SS., Competing Interests: CONFLICTS OF INTEREST The authors declare no conflicts of interest.
- Published
- 2019
- Full Text
- View/download PDF
32. Staphylococcal alpha-toxin tilts the balance between malignant and non-malignant CD4 + T cells in cutaneous T-cell lymphoma.
- Author
-
Blümel E, Willerslev-Olsen A, Gluud M, Lindahl LM, Fredholm S, Nastasi C, Krejsgaard T, Surewaard BGJ, Koralov SB, Hu T, Persson JL, Bonefeld CM, Geisler C, Iversen L, Becker JC, Andersen MH, Woetmann A, Buus TB, and Ødum N
- Abstract
Staphylococcus aureus is implicated in disease progression in cutaneous T-cell lymphoma (CTCL). Here, we demonstrate that malignant T cell lines derived from CTCL patients as well as primary malignant CD4
+ T cells from Sézary syndrome patients are considerably more resistant to alpha-toxin-induced cell death than their non-malignant counterparts. Thus, in a subset of Sézary syndrome patients the ratio between malignant and non-malignant CD4+ T cells increases significantly following exposure to alpha-toxin. Whereas toxin-induced cell death is ADAM10 dependent in healthy CD4+ T cells, resistance to alpha-toxin in malignant T cells involves both downregulation of ADAM10 as well as other resistance mechanisms. In conclusion, we provide first evidence that Staphylococcus aureus derived alpha-toxin can tilt the balance between malignant and non-malignant CD4+ T cells in CTCL patients. Consequently, alpha-toxin may promote disease progression through positive selection of malignant CD4+ T cells, identifying alpha-toxin as a putative drug target in CTCL., (© 2019 The Author(s). Published with license by Taylor & Francis Group, LLC.)- Published
- 2019
- Full Text
- View/download PDF
33. Single-cell heterogeneity in Sézary syndrome.
- Author
-
Buus TB, Willerslev-Olsen A, Fredholm S, Blümel E, Nastasi C, Gluud M, Hu T, Lindahl LM, Iversen L, Fogh H, Gniadecki R, Litvinov IV, Persson JL, Bonefeld CM, Geisler C, Christensen JP, Krejsgaard T, Litman T, Woetmann A, and Ødum N
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Depsipeptides pharmacology, Drug Resistance, Neoplasm, Flow Cytometry, Histone Deacetylase Inhibitors pharmacology, Sezary Syndrome drug therapy, Sezary Syndrome metabolism, Sezary Syndrome pathology, T-Lymphocytes metabolism, T-Lymphocytes pathology, Vorinostat pharmacology
- Abstract
Sézary syndrome (SS) is an aggressive leukemic variant of cutaneous T-cell lymphoma (CTCL) with a median life expectancy of less than 4 years. Although initial treatment responses are often good, the vast majority of patients with SS fail to respond to ongoing therapy. We hypothesize that malignant T cells are highly heterogeneous and harbor subpopulations of SS cells that are both sensitive and resistant to treatment. Here, we investigate the presence of single-cell heterogeneity and resistance to histone deacetylase inhibitors (HDACi) within primary malignant T cells from patients with SS. Using single-cell RNA sequencing and flow cytometry, we find that malignant T cells from all investigated patients with SS display a high degree of single-cell heterogeneity at both the mRNA and protein levels. We show that this heterogeneity divides the malignant cells into distinct subpopulations that can be isolated by their expression of different surface antigens. Finally, we show that treatment with HDACi (suberanilohydroxamic acid and romidepsin) selectively eliminates some subpopulations while leaving other subpopulations largely unaffected. In conclusion, we show that patients with SS display a high degree of single-cell heterogeneity within the malignant T-cell population, and that distinct subpopulations of malignant T cells carry HDACi resistance. Our data point to the importance of understanding the heterogeneous nature of malignant SS cells in each individual patient to design combinational and new therapies to counter drug resistance and treatment failure., (© 2018 by The American Society of Hematology.)
- Published
- 2018
- Full Text
- View/download PDF
34. Butyrate and propionate inhibit antigen-specific CD8 + T cell activation by suppressing IL-12 production by antigen-presenting cells.
- Author
-
Nastasi C, Fredholm S, Willerslev-Olsen A, Hansen M, Bonefeld CM, Geisler C, Andersen MH, Ødum N, and Woetmann A
- Subjects
- CD8-Positive T-Lymphocytes immunology, Cells, Cultured, Coculture Techniques, Dendritic Cells immunology, Humans, Interleukin-23 metabolism, MART-1 Antigen metabolism, Butyrates pharmacology, CD8-Positive T-Lymphocytes drug effects, Dendritic Cells drug effects, Immunologic Factors pharmacology, Interleukin-12 metabolism, Propionates pharmacology
- Abstract
Short chain fatty acids (SCFAs), such as acetate, butyrate and propionate, are products of microbial macronutrients fermentation that distribute systemically and are believed to modulate host immune responses. Recent data have indicated that certain SCFAs, such as butyrate and propionate, directly modulate human dendritic cell (DC) function. Given the role of DCs in initiating and shaping the adaptive immune response, we now explore how SCFAs affect the activation of antigen-specific CD8
+ T cells stimulated with autologous, MART1 peptide-pulsed DC. We show that butyrate reduces the frequency of peptide-specific CD8+ T cells and, together with propionate, inhibit the activity of those cells. On the contrary, acetate does not affect them. Importantly, butyrate and propionate inhibit the production of IL-12 and IL-23 in the DCs and exogenous IL-12 fully restores the activation of the MART-1-specific CD8+ T cells, whereas IL-23 has no effect. In conclusion, these results point to a pivotal role of butyrate and propionate in modulating CD8+ T cell activation via the inhibition of IL-12 secretion from DCs. These findings reveal a novel mechanism whereby bacterial fermentation products may modulate CD8+ T cell function with possible implications in anti-cancer immunotherapy.- Published
- 2017
- Full Text
- View/download PDF
35. A novel BLK-induced tumor model.
- Author
-
Petersen DL, Berthelsen J, Willerslev-Olsen A, Fredholm S, Dabelsteen S, Bonefeld CM, Geisler C, and Woetmann A
- Subjects
- Animals, B-Lymphocytes pathology, Cell Line, Tumor, Disease Models, Animal, Gene Expression Regulation, Neoplastic, Humans, Lymphoma, T-Cell, Cutaneous pathology, Mice, Proto-Oncogene Mas, Signal Transduction, Xenograft Model Antitumor Assays, src-Family Kinases biosynthesis, Carcinogenesis genetics, Lymphocyte Activation genetics, Lymphoma, T-Cell, Cutaneous genetics, src-Family Kinases genetics
- Abstract
B-lymphoid tyrosine kinase (BLK) is a non-receptor tyrosine kinase belonging to the SRC family kinases. BLK is known to be functionally involved in B-cell receptor signaling and B-cell development. New evidence suggests that B-lymphoid tyrosine kinase is ectopically expressed and is a putative oncogene in cutaneous T-cell lymphoma and other T-cell malignancies. However, little is known about the role of BLK in lymphomagenesis, and the oncogenic function seems to depend on the cellular context. Importantly, BLK is also ectopically expressed in other hematological and multiple non-hematological malignancies including breast, kidney, and lung cancers, suggesting that BLK could be a new potential target for therapy. Here, we studied the oncogenic potential of human BLK. We found that engrafted Ba/F3 cells stably expressing constitutive active human BLK formed tumors in mice, whereas neither Ba/F3 cells expressing wild type BLK nor non-transfected Ba/F3 cells did. Inhibition of BLK with the clinical grade and broadly reacting SRC family kinase inhibitor dasatinib inhibited growth of BLK-induced tumors. In conclusion, our study provides evidence that human BLK is a true proto-oncogene capable of inducing tumors, and we demonstrate a novel BLK activity-dependent tumor model suitable for studies of BLK-driven lymphomagenesis and screening of novel BLK inhibitors in vivo.
- Published
- 2017
- Full Text
- View/download PDF
36. STAT5 induces miR-21 expression in cutaneous T cell lymphoma.
- Author
-
Lindahl LM, Fredholm S, Joseph C, Nielsen BS, Jønson L, Willerslev-Olsen A, Gluud M, Blümel E, Petersen DL, Sibbesen N, Hu T, Nastasi C, Krejsgaard T, Jæhger D, Persson JL, Mongan N, Wasik MA, Litvinov IV, Sasseville D, Koralov SB, Bonefeld CM, Geisler C, Woetmann A, Ralfkiaer E, Iversen L, and Odum N
- Subjects
- Female, Humans, Lymphoma, T-Cell, Cutaneous genetics, Male, MicroRNAs genetics, STAT5 Transcription Factor genetics, Skin Neoplasms genetics, Gene Expression Regulation, Neoplastic physiology, Lymphoma, T-Cell, Cutaneous metabolism, MicroRNAs biosynthesis, STAT5 Transcription Factor metabolism, Skin Neoplasms metabolism
- Abstract
In cutaneous T cell lymphomas (CTCL), miR-21 is aberrantly expressed in skin and peripheral blood and displays anti-apoptotic properties in malignant T cells. It is, however, unclear exactly which cells express miR-21 and what mechanisms regulate miR-21. Here, we demonstrate miR-21 expression in situ in both malignant and reactive lymphocytes as well as stromal cells. qRT-PCR analysis of 47 patients with mycosis fungoides (MF) and Sezary Syndrome (SS) confirmed an increased miR-21 expression that correlated with progressive disease. In cultured malignant T cells miR-21 expression was inhibited by Tofacitinib (CP-690550), a clinical-grade JAK3 inhibitor. Chromatin immunoprecipitation (ChIP) analysis showed direct binding of STAT5 to the miR-21 promoter. Cytokine starvation ex vivo triggered a decrease in miR-21 expression, whereas IL-2 induced an increased miR-21 expression in primary SS T cells and cultured cytokine-dependent SS cells (SeAx). siRNA-mediated depletion of STAT5 inhibited constitutive- and IL-2-induced miR-21 expression in cytokine-independent and dependent T cell lines, respectively. IL-15 and IL-2 were more potent than IL-21 in inducing miR-21 expression in the cytokine-dependent T cells. In conclusion, we provide first evidence that miR-21 is expressed in situ in CTCL skin lesions, induced by IL-2 and IL-15 cytokines, and is regulated by STAT5 in malignant T cells. Thus, our data provide novel evidence for a pathological role of IL-2Rg cytokines in promoting expression of the oncogenic miR-21 in CTCL., Competing Interests: The authors declare no conflicts of interest.
- Published
- 2016
- Full Text
- View/download PDF
37. The Expression of IL-21 Is Promoted by MEKK4 in Malignant T Cells and Associated with Increased Progression Risk in Cutaneous T-Cell Lymphoma.
- Author
-
Fredholm S, Litvinov IV, Mongan NP, Schiele S, Willerslev-Olsen A, Petersen DL, Krejsgaard T, Sibbesen N, Nastasi C, Bonefeld CM, Persson JL, Straten PT, Andersen MH, Koralov SB, Wasik MM, Geisler C, Sasseville D, Woetmann A, and Ødum N
- Subjects
- Disease Progression, Humans, Inflammation, Interleukins genetics, MAP Kinase Signaling System, Phosphorylation, RNA, Small Interfering metabolism, STAT3 Transcription Factor metabolism, Signal Transduction, Gene Expression Regulation, Neoplastic, Interleukins metabolism, Lymphoma, T-Cell metabolism, MAP Kinase Kinase Kinase 4 metabolism, Skin Neoplasms metabolism, T-Lymphocytes metabolism
- Published
- 2016
- Full Text
- View/download PDF
38. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
- Author
-
Sibbesen NA, Kopp KL, Litvinov IV, Jønson L, Willerslev-Olsen A, Fredholm S, Petersen DL, Nastasi C, Krejsgaard T, Lindahl LM, Gniadecki R, Mongan NP, Sasseville D, Wasik MA, Iversen L, Bonefeld CM, Geisler C, Woetmann A, and Odum N
- Subjects
- Cell Line, Tumor, Genes, Tumor Suppressor, Humans, Janus Kinase 3 antagonists & inhibitors, Janus Kinase 3 genetics, Lymphoma, T-Cell, Cutaneous metabolism, Lymphoma, T-Cell, Cutaneous pathology, MicroRNAs administration & dosage, MicroRNAs biosynthesis, MicroRNAs genetics, Piperidines pharmacology, Protein Kinase Inhibitors pharmacology, Pyrimidines pharmacology, Pyrroles pharmacology, STAT3 Transcription Factor genetics, STAT5 Transcription Factor genetics, Signal Transduction, Skin Neoplasms metabolism, Skin Neoplasms pathology, Transfection, Janus Kinase 3 metabolism, Lymphoma, T-Cell, Cutaneous genetics, MicroRNAs antagonists & inhibitors, STAT3 Transcription Factor metabolism, STAT5 Transcription Factor metabolism, Skin Neoplasms genetics
- Abstract
Aberrant activation of Janus kinase-3 (Jak3) and its key down-stream effectors, Signal Transducer and Activator of Transcription-3 (STAT3) and STAT5, is a key feature of malignant transformation in cutaneous T-cell lymphoma (CTCL). However, it remains only partially understood how Jak3/STAT activation promotes lymphomagenesis. Recently, non-coding microRNAs (miRNAs) have been implicated in the pathogenesis of this malignancy. Here, we show that (i) malignant T cells display a decreased expression of a tumor suppressor miRNA, miR-22, when compared to non-malignant T cells, (ii) STAT5 binds the promoter of the miR-22 host gene, and (iii) inhibition of Jak3, STAT3, and STAT5 triggers increased expression of pri-miR-22 and miR-22. Curcumin, a nutrient with anti-Jak3 activity and histone deacetylase inhibitors (HDACi) also trigger increased expression of pri-miR-22 and miR-22. Transfection of malignant T cells with recombinant miR-22 inhibits the expression of validated miR-22 targets including NCoA1, a transcriptional co-activator in others cancers, as well as HDAC6, MAX, MYCBP, PTEN, and CDK2, which have all been implicated in CTCL pathogenesis. In conclusion, we provide the first evidence that de-regulated Jak3/STAT3/STAT5 signalling in CTCL cells represses the expression of the gene encoding miR-22, a novel tumor suppressor miRNA.
- Published
- 2015
- Full Text
- View/download PDF
39. STAT3 activation and infiltration of eosinophil granulocytes in mycosis fungoides.
- Author
-
Fredholm S, Gjerdrum LM, Willerslev-Olsen A, Petersen DL, Nielsen IØ, Kauczok CS, Wobser M, Ralfkiaer U, Bonefeld CM, Wasik MA, Krejsgaard T, Geisler C, Ralfkiaer E, Gniadecki R, Woetmann A, and Odum N
- Subjects
- Biopsy, Cell Line, Tumor, Gene Knockout Techniques, HMGB1 Protein genetics, HMGB1 Protein metabolism, Humans, Immunohistochemistry, Interleukin-5 genetics, Interleukin-5 metabolism, Mycosis Fungoides genetics, Mycosis Fungoides immunology, RNA Interference, STAT3 Transcription Factor genetics, T-Lymphocytes immunology, T-Lymphocytes metabolism, T-Lymphocytes pathology, Eosinophils pathology, Mycosis Fungoides metabolism, Mycosis Fungoides pathology, STAT3 Transcription Factor metabolism
- Abstract
Eosinophil granulocytes have been implicated in anticancer immunity but recent data indicate that eosinophils can also promote cancer. Herein, we studied eosinophils in skin lesions from 43 patients with mycosis fungoides (MF). The presence of eosinophils correlated with disease stage: 78% of patients with advanced disease displayed eosinophil infiltration, whereas this was only seen in 11% of patients with patches (p<0.01), and in 48% of those with plaque disease. Importantly, 72% of patients with positive staining for phospho-signal-transducer-and-activator-of-transcription (pY-STAT3) in malignant T-cells also stained positively for eosinophils, whereas this was only observed in 28% of pY-STAT3-negative patients (p<0.01). Notably, malignant T-cells expressed eosinophilic activation and trafficking factors: High-mobility group BOX-1 protein (HMGB1) and interleukin 5 (IL5). STAT3 siRNA profoundly inhibited IL5 but not HMGB1 expression. In conclusion, these data suggest that malignant T-cells orchestrate accumulation and activation of eosinophils supporting the notion of STAT3 being a putative target for therapy., (Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)
- Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.